Merck is exploring significant acquisition opportunities, according to CEO Rob Davis, who spoke at the J.P. Morgan Healthcare Conference. The company has been linked in speculation to a potential $30 billion purchase of Revolution Medicines, although Davis did not confirm any specific deals.
“We are not limited from a balance sheet,” Davis said during his presentation. “It’s more where do we see strategic opportunity.” He added that Merck’s target range for acquisitions could be in the “multi tens of billions of dollars,” joking about Chief Financial Officer Caroline Litchfield’s oversight: “I’ve got to look at my CFO [Caroline Litchfield]. I would spend more, she won’t let me.”
Revolution Medicines is working on targeted drugs for RAS-driven cancers and has also been rumored as an acquisition target for AbbVie. However, AbbVie denied any ongoing talks with Revolution after announcing plans to invest $100 billion into its U.S. research and manufacturing over the next decade.
BMO Capital Markets analysts observed a shift in Merck’s outlook compared to previous years. In their note to investors, they wrote: “Thinking back on Merck’s presentation last year, we note new confidence from management, with raised mid-2030s guidance for new growth drivers (+$20B since last year).” BMO reported that Merck increased its long-term estimates by $5 billion for its cardiometabolic/respiratory portfolio, by $10 billion for infectious diseases, and raised ophthalmology projections from “multibillion” to greater than $5 billion.
Davis highlighted the company’s optimism about future commercial prospects: “The success and progress we’ve had to date now puts us in a position where we see visibility to more than $70 billion of commercial opportunity as we look out to the mid-2030s.”
Addressing concerns about Keytruda losing exclusivity in coming years—a major event given the drug's significance—Davis said he was confident in managing this transition: “I couldn’t be more confident as I sit here today.” He described Keytruda’s loss of exclusivity period as “more of a hill than a cliff,” adding: “I’m quite confident that we will be in a position at a minimum to go through a very shallow period post the LOE, returning in a few years to growth.”
BMO responded positively to these remarks: “We view commentary from Rob Davis suggesting growth through the LOE is still possible as increasingly positive and realization of such results would be beyond our current expectations today, pushing for greater MRK upside.”
